Tradestie Institutional Equity Comparison Engine
VTAK vs ERNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VTAK Overall Edge
VTAK Captures Institutional Edge (1โ1 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Catheter Precision, Inc. (VTAK) driven by superior Growth & Margin while ERNA counters with relative strength in Momentum & Technical. Fundamentally, VTAK trades at N/M Forward P/E with -388.1% operating margin (+380.7% YoY revenue) versus ERNA at N/M Forward P/E and 0.0% operating margin (-94.1% YoY). In options structure, VTAK sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ERNA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VTAK N/M vs ERNA N/M Fwd P/E
Growth & Margin Winner
VTAK
Op Margin -388.1% vs 0.0% ยท YoY +380.7% vs -94.1%
Momentum & Technical Winner
ERNA
1Y -94.3% vs +7.6% ยท 52W Pos 1% vs 10%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
VTAK
NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap
$548,639
1M Return
-24.76%
1Y Return
-94.28%
Forward P/E
N/M
Unified AI Score
58.1 / 100
HOLD
Tech 72.0
Fund 70.0
Flow 50.0
Mom 60.0
ERNA
NASDAQ
Ernexa Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$1.69
+0.6% 1D
Market Cap
$2.8M
1M Return
-19.14%
1Y Return
+7.64%
Forward P/E
N/M
Unified AI Score
45.6 / 100
HOLD
Tech 36.0
Fund 50.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VTAK -94.28%
ERNA +7.64%
Spread: +181.17 pp (ERNA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VTAK Revenue | ERNA Revenue | VTAK Op. Margin | ERNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | $20M | -498.0% | 0.9% | ERNA |
| FY2019 | $10M | $20M | -801.9% | -8.9% | ERNA |
| FY2020 | $0M | $10M | -13668.3% | -125.0% | ERNA |
| FY2021 | $0M | N/A | -133027.3% | N/A | VTAK |
| FY2022 | $0M | N/A | -192578.6% | N/A | VTAK |
| FY2023 | $0M | $0M | -17674.0% | -31080.9% | VTAK |
| FY2024 | $0M | $0M | -2676.9% | -2693.1% | VTAK |
| FY2025 | $0M | N/A | -2581.6% | N/A | VTAK |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VTAK | ERNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $548,639 | $2.8M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +380.7% | -94.1% | Higher Growth | VTAK |
| Operating Margin (TTM) Profitability | -388.1% | 0.0% | Higher Margin | ERNA |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -111.3% | -320.7% | Higher ROE | VTAK |
| 52-Week Range Position Momentum | 1% ($0โ$3) | 10% ($0โ$16) | Stronger Trend | ERNA |
| Beta / 30D Volatility Risk Regime | 0.19ฮฒ ยท 76% Vol | -5.48ฮฒ ยท 90% Vol | Lower Realized Risk | VTAK |
| Unified Institutional Score Composite Signal | 58.1 / 100 (HOLD) | 45.6 / 100 (HOLD) | Higher Composite | VTAK |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VTAK vs ERNA Buy Guide
VTAK
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ERNA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VTAK nor ERNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.